{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:57:47Z","timestamp":1776959867737,"version":"3.51.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Tripterygium wilfordii Hook. F (TwHF), a Chinese herbal medicine used to treat CTD-ILD patients in China, has been previously found to have immunoinhibitory, antifibrotic and anti inflammatory effects. It has also shown good results in treating autoimmune and inflammatory diseases.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> This systematic review and meta-analysis aims to evaluate the efficacy and safety of TwHF for CTD-ILD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic search was performed on PubMed, Embase, Cochrane Library, Web of Science, PsycINFO, Scopus, CNKI, Wanfang, VIP, and CBM databases up to May 2021. Randomized controlled trials (RCTs) comparing TwHF plus conventional therapy versus conventional therapy alone were included. We followed the PRISMA checklist, and applied Cochrane handbook 5.1.0 and RevMan 5.3 for data analysis and quality evaluation of the included studies.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Based on Cochrane handbook 5.1.0, nine RCTs consisting 650 patients met the inclusion\/exclusion criteria and were selected for further analysis. The obtained data showed significant improvement in lung function with TwHF plus conventional treatment compared with conventional treatment (post-treatment FVC% (MD= 8.68, 95%Cl (5.10, 12.26), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), FEV1% (MD = 11.24, 95%Cl (6.87, 15.61), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), TLC% (MD = 5.28, 95%Cl (0.69, 9.87), <jats:italic>p<\/jats:italic> = 0.02)], but no significant difference in the post-treatment DLCO% [(MD = 4.40, 95%Cl (\u22122.29, 11.09), <jats:italic>p<\/jats:italic> = 0.20)]. Moreover, the data showed that TwHF combined with conventional treatment significantly reduced the HRCT integral of patients [MD = -0.65, 95% (-1.01, -0.30), <jats:italic>p =<\/jats:italic> 0.0003], the level of erythrocyte sedimentation rate (MD = \u22129.52, 95%Cl (\u221211.55, \u22127.49), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), c-reactive protein (CRP) (MD = \u22128.42, 95%Cl (\u221212.47, \u22124.38), <jats:italic>p<\/jats:italic> &amp;lt; 0.0001), and rheumatoid factor (MD = \u221225.48, 95%Cl (\u221229.36, \u221221.60), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001). Compared to conventional therapy, TwHF combined with conventional therapy significantly improved clinical effects (RR = 1.33, 95%Cl (1.17, 1.51), <jats:italic>p<\/jats:italic> &amp;lt; 0.0001), in five trials with 354 patients. In terms of improvement of symptoms and signs, the TwHF group showed a more significant improvement than the conventional treatment group (Cough (MD = \u22120.96, 95%Cl (\u22121.43, \u22120.50), <jats:italic>p<\/jats:italic> &amp;lt; 0.0001), velcro rales (MD = \u22120.32, 95%Cl (\u22120.44, \u22120.20), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), shortness of breath (MD = \u22121.11, 95%Cl (\u22121.67, \u22120.56), <jats:italic>p<\/jats:italic> &amp;lt; 0.0001)], but no statistical difference in dyspnea (MD = \u22120.66, 95%Cl (\u22121.35, 0.03), <jats:italic>p<\/jats:italic> = 0.06). There was no statistical significance in the incidence of adverse reactions.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The performed meta-analysis indicated that TwHF combined with conventional treatment was more beneficial to patients for improving symptoms, lung function and laboratory indicators. As it included studies with relatively small sample size, the findings require confirmation by further rigorously well-designed RCTs.<\/jats:p>","DOI":"10.3389\/fphar.2021.691031","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:45:44Z","timestamp":1623314744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Disease-Associated Interstitial Lung Disease:A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yehui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yordan Angelov","family":"Garov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology\/European League against Rheumatism Collaborative Initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B2","first-page":"1098","article-title":"Secondary Sj\u00f6gren's Syndrome in Rheumatoid Arthritis","volume":"14","author":"Andonopoulos","year":"1987","journal-title":"J. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/1744666x.2018.1411190","article-title":"Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: a Comprehensive Review","volume":"14","author":"Atzeni","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1148\/radiology.200.2.8685321","article-title":"Glossary of Terms for CT of the Lungs: Recommendations of the Nomenclature Committee of the Fleischner Society","volume":"200","author":"Austin","year":"1996","journal-title":"Radiology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7501\/j.issn.0253-2670.2020.01.034","article-title":"Research Progress of Tripterygium Wilfordii in Treatment of Rheumatoid Arthritis","volume":"51","author":"Bai","year":"2020","journal-title":"Chin. Tradit Herbal Durgs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00296-011-1841-y","article-title":"A Chinese Herb Tripterygium Wilfordii Hook F in the Treatment of Rheumatoid Arthritis: Mechanism, Efficacy, and Safety","volume":"31","author":"Bao","year":"2011","journal-title":"Rheumatol. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e21909","DOI":"10.1097\/md.0000000000021909","article-title":"Tripterygium and its Plant Extraction for Systemic Lupus Erythematosus","volume":"99","author":"Chen","year":"","journal-title":"Medicine (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14900","DOI":"10.4238\/2015.November.18.55","article-title":"Effects of Tripterygium Wilfordii Glycosides on Regulatory T Cells and Th17 in an IgA Nephropathy Rat Model","volume":"14","author":"Chen","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3969\/j.issn.1674-4721.2020.29.010","article-title":"Clinical Effect of Tripterygium Glycosides in the Treatment of Connective Tissue Disease-Related Interstitial Lung Disease","volume":"27","author":"Chen","year":"","journal-title":"China Mod. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3969\/j.issn.1673-7202.2020.04.023","article-title":"Analysis of Clinical Efficacy of Tripterygium Wilfordii Glycosides Combined with Prednisone in the Treatment of Rheumatoid Arthritis with Interstitial Lung Disease","volume":"15","author":"Chen","year":"","journal-title":"World Chin. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fphar.2018.00104","article-title":"A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium Wilfordii Hook F","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann. ATS"},{"key":"B13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/01.bor.0000434670.39773.a8","article-title":"Lung Transplantation in Patients with Scleroderma","volume":"25","author":"De Cruz","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"B14","first-page":"20","article-title":"Preliminary Clinical Observation of Tripterygium Wilfordii Polyglycoside in the Treatment of Connective Tissue Disease Related Interstitial Lung Disease","volume":"14","author":"Dong","year":"2017","journal-title":"China Rural Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","article-title":"Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease","volume":"38","author":"Duarte","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.16306\/j.1008-861x.2017.02.010","article-title":"To Investigate the Clinical Effect of Glucocorticoid Combined with Tripterygium Glycosides in the Treatment of Connective Tissue Disease Related Interstitial Lung Disease","volume":"20","author":"Fan","year":"2020","journal-title":"World Latest Med. Inf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"108669","DOI":"10.1016\/j.biopha.2019.108669","article-title":"Citrus Alkaline Extracts Prevent Fibroblast Senescence to Ameliorate Pulmonary Fibrosis via Activation of COX-2","volume":"112","author":"Feng","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s10067-019-04720-0","article-title":"Progressive Fibrosing Interstitial Lung Disease Associated with Systemic Autoimmune Diseases","volume":"38","author":"Fischer","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.16485\/j.issn.2095-7858.2020.02.017","article-title":"Effect of Tripterygium Glycosides Combined with Methotrexate Tablets in the Treatment of Pulmonary Interstitial Lesions in Rheumatoid Arthritis","volume":"18","author":"Gao","year":"2020","journal-title":"J. Bethune. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.mayocp.2019.07.007","article-title":"Treatment of the Connective Tissue Disease-Related Interstitial Lung Diseases: A Narrative Review","volume":"95","author":"Gao","year":"2020","journal-title":"Mayo Clinic Proc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1479-5876-11-134","article-title":"Treatment of Diabetic Nephropathy with Tripterygium Wilfordii Hook F Extract: a Prospective, Randomized, Controlled Clinical Trial","volume":"11","author":"Ge","year":"2013","journal-title":"J. Translational Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"L830","DOI":"10.1152\/ajplung.00014.2010","article-title":"Identification of Triptolide, a Natural Diterpenoid Compound, as an Inhibitor of Lung Inflammation","volume":"298","author":"Hoyle","year":"2010","journal-title":"Am. J. Physiology-Lung Cell Mol. Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.3969\/j.issn.1006-5725.2015.19.042","article-title":"Preliminary Clinical Observation of Tripterygium Wilfordii Polyglycoside in the Treatment of Connective Tissue Disease Related Interstitial Lung Disease","volume":"31","author":"Hu","year":"2015","journal-title":"J. Pract. Tradit Chin. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5276865","article-title":"A Network Pharmacology Study on the Active Ingredients and Potential Targets ofTripterygium wilfordiiHook for Treatment of Rheumatoid Arthritis","volume":"2019","author":"Hu","year":"2019","journal-title":"Evidence-Based Complement. Altern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s40265-019-01178-x","article-title":"Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)","volume":"79","author":"Jee","year":"2019","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3892\/mmr.2015.3448","article-title":"Beneficial Effects of Tripterygium Glycosides Tablet on Biomarkers in Patients with Ankylosing Spondylitis","volume":"12","author":"Ji","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phytochem.2010.10.015","article-title":"Molecular Analyses of the Chinese Herb Leigongteng (Tripterygium Wilfordii Hook.f.)","volume":"72","author":"Law","year":"2011","journal-title":"Phytochemistry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/348450","article-title":"Changes of CD4+CD25+Regulatory T Cells, FoxP3 in Adjuvant Arthritis Rats with Damage of Pulmonary Function and Effects of Tripterygium Glycosides Tablet","volume":"2012","author":"Lei","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s10067-015-3043-6","article-title":"Efficacy of Tripterygium Glycosides Tablet in Treating Ankylosing Spondylitis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"34","author":"Li","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.13193\/j.issn.1673-7717.2017.07.007","article-title":"Clinical Research on Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease by Tripterygium Glycosides","volume":"35","author":"Li","year":"2017","journal-title":"Chin. J. Tradit Chin. Med. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.16306\/j.1008-861x.2017.02.010","article-title":"Clinical Observation on Glucocorticoids Combined with Tripterygium Glycosides in the Treatment of CTD-ILD","volume":"31","author":"Lin","year":"2017","journal-title":"J. Shanghai Univ. Chin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.13507\/j.issn.1674-3474.2014.12.038","article-title":"Therapeutic Effect of Tripterygium Glycosides Plus Prednisone on Moderate Active Systemic Lupus Erythematosus","volume":"28","author":"Liu","year":"2014","journal-title":"J. Chin. Pract. Diagn. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11684-018-0649-5","article-title":"Immunoregulatory Effects of Tripterygium Wilfordii Hook F and its Extracts in Clinical Practice","volume":"13","author":"Luo","year":"2019","journal-title":"Front. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2623085","article-title":"Efficacy and Safety of Tripterygium Wilfordii Hook F on Psoriasis Vulgaris: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"2018","author":"Lv","year":"2018","journal-title":"Evidence-Based Complement. Altern. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/annrheumdis-2013-204807","article-title":"Comparison of Tripterygium Wilfordii Hook F with Methotrexate in the Treatment of Active Rheumatoid Arthritis (TRIFRA): a Randomised, Controlled Clinical Trial","volume":"74","author":"Lv","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s2213-2600(19)30341-8","article-title":"Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: a Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of Interstitial Lung Disease Associated with Connective Tissue Disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.mayocp.2018.09.002","article-title":"Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases","volume":"94","author":"Mira-Avendano","year":"2019","journal-title":"Mayo Clinic Proc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMc1910735","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"381","author":"Moran-Mendoza","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.semarthrit.2020.07.011","article-title":"Risk of Interstitial Lung Disease in Patients with Newly Diagnosed Systemic Autoimmune Rheumatic Disease: A Nationwide, Population-Based Cohort Study","volume":"50","author":"Ng","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"B42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.13412\/j.cnki.zyyl.20210104.002","article-title":"To Explore the Mechanism of Chenpi in the Treatment of Pulmonary Fibrosis Based on Network Pharmacology and Experimental Verification","volume":"1","author":"Peng","year":"2021","journal-title":"Phar. Clin. Chin. Mater. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung Transplantation for Scleroderma Lung Disease: An International, Multicenter, Observational Cohort Study","volume":"37","author":"Prad\u00e8re","year":"2018","journal-title":"J. Heart Lung Transplant."},{"key":"B44","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An Official ATS\/ERS\/JRS\/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3760\/cma.j.issn.0578-1426.2018.08.005","article-title":"2018 Chinese Expert-Based Consensus Statement Regarding the Diagnosis and Treatment of Interstitial Lung Disease Associated with Connective Tissue Diseases","volume":"57","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective Tissue Disease Related Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: Provisional Core Sets of Domains and Instruments for Use in Clinical Trials","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"key":"B47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-Induced Interstitial Lung Disease: A Systematic Review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J. Clin. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification Criteria for Sjogren's Syndrome: a Revised Version of the European Criteria Proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1159\/000490472","article-title":"Different Doses of Tripterygium Glycosides in the Treatment of Diabetic Nephropathy: Effects on Blood Lipids","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10753-014-9858-5","article-title":"Anti-inflammatory Effects of Triptolide in LPS-Induced Acute Lung Injury in Mice","volume":"37","author":"Wei","year":"2014","journal-title":"Inflammation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial Lung Disease in Connective Tissue Disease-Mechanisms and Management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.13621\/j.1001-5949.2017.06.0499","article-title":"Effect of Tripterygium Polyglucoside in the Patients of Primary Sjogren's syndrome-Associated Interstitial Lung Disease","volume":"39","author":"Yang","year":"2017","journal-title":"Ningxia Med. J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.13261\/j.cnki.jfutcm.002499","article-title":"Intervention of Tripterygium Glycosides on Pulmonary Fibrosis","volume":"21","author":"Yang","year":"2011","journal-title":"Rehabil. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3389\/fphar.2019.01469","article-title":"Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases-A Review","volume":"10","author":"Yuan","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3760\/cma.j.issn.1001-0939.2009.07.014","article-title":"The Differential Diagnosis of Interstitial Pneumonia Associated with Connective Tissue Diseases from Idiopathic Interstitial Pneumonia","volume":"32","author":"Zhang","year":"2009","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.16333\/j.1001-6880.2021.3.016","article-title":"Study on the Molecular Mechanism of Tripterygium Wilfordii in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease Based on Network Pharmacology and Molecular Docking","volume":"33","author":"Zhang","year":"2021","journal-title":"Nat. Prod. Res. Dev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.13683\/j.wph.2018.06.015","article-title":"Progress in the Treatment of Connective Tissue Disease Related Interstitial Lung Disease","volume":"39","author":"Zhao","year":"2018","journal-title":"J. World Clin. Drugs"},{"key":"B58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphar.2018.00356","article-title":"The Effectiveness and Safety of Tripterygium Wilfordii Hook. F Extracts in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"9","author":"Zhou","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.691031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:46:03Z","timestamp":1623314763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.691031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":58,"alternative-id":["10.3389\/fphar.2021.691031"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.691031","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"article-number":"691031"}}